Basic information of Levodopa
- Product Name: Levodopa
- Common abbreviations: L-Dopa; L-DOPA
- CAS No.: 59-92-7
- EINECS No.: 200-445-2
- Molecular Formula: C9H11NO4
- Molecular Weight: 197.19
- Packaging Specifications: e.g., 25kg/drum, or customized according to customer requirements.
- Production Facilities: Modern production line compliant with GMP standards.
Highassay’s Levodopa
- Highassay is a Chinese supplier of Levodopa raw materials.We provide high-quality, high-purity Levodopa raw materials and can supply globally.
- Highassay’s Levodopa active pharmaceutical ingredient complies with multiple pharmacopoeias, including USP/BP/EP/IP.A complete set of quality inspection reports and data are included with the product.
- As Parkinson’s disease API supplier, Highassay supplies both Levodopa and high-purity Carbidopa raw material.As a golden combination for treating Parkinson’s disease, it provides convenience for your procurement.
- Levodopa has long been the gold standard drug for the treatment of Parkinson’s disease.Highassay has a stable and long-term supply capability and a strict quality system.When purchasing Levodopa raw materials, please look for Highassay.
What is Levodopa?
- Levodopa is the core active ingredient in the treatment of Parkinson’s disease and Parkinsonian syndrome.However, it needs to be used in conjunction with carbidopa.
- The combined use of Levodopa and Carbidopa.It can not only reduce the dosage of levodopa, but also reduce the side effects of taking Levodopa.
- Levodopa itself has no direct pharmacological activity.It needs to enter the central nervous system and be converted into dopamine by dopacarase before it can exert its effects.
- Levodopa is a prodrug of dopamine.It can cross the blood-brain barrier to enter the brain, where it is converted and replenishes dopamine in the patient’s brain.It helps improve symptoms such as tremors and muscle stiffness.
- Levodopa can relieve symptoms such as muscle rigidity and bradykinesia.And also can be used for diseases such as hepatic encephalopathy and neuralgia.
- The initial oral dose of Levodopa is 250 mg daily, divided into 2-4 doses, with a maximum daily dose not exceeding 6 g.Overdose of Levodopa can easily cause motor disorders.
- Common adverse reactions of Levodopa：Gastrointestinal reactions, orthostatic hypotension, and long-term use may cause mental symptoms.
- Contraindications of Levodopa：Glaucoma patients, pregnant women, and breastfeeding women are prohibited from using this product.
- Levodopa should be avoided in combination with monoamine oxidase inhibitors and vitamin B6.
Physicochemical Properties of Levodopa
- Appearance and Odor: White or off-white crystalline powder; odorless and tasteless.
- Solubility: Slightly soluble in water; almost insoluble in ethanol, chloroform, and ether; readily soluble in dilute hydrochloric acid and dilute nitric acid.
- Melting Point: 276-278℃ (decomposes upon heating above the melting point, but does not melt).
- Stability: Easily oxidizes and discolors upon exposure to light and air; unstable under alkaline conditions.
- Storage: Should be protected from light, sealed, and stored in a cool, dry place. Research storage is recommended at 2-8℃ or -20℃.
Certificate of Levodopa’s Analysis
- Certificate of Levodopa’s Analysis
| Items | Specification |
| Characters | A white to off-white crystalline powder , odorless |
| Solubility | Meet USP requirements |
| Identification | A) Infrared absorption spectrum B) Absorbance C) RT |
| Specific optical rotation | -160° ~ -167° |
| Loss on drying | 0.5% max |
| Residue on ignition | 0.1% max |
| Heavy metals | 0.002% max |
| Related compounds | Levadopa related compound A: 0.1% max L-tyrosin : 0.1% max 3-mehtoxytyrosine: 0.5% max 1-veratrylglycine: 0.1%max Any unknown impurity:0.1% max The sum of all impurities : 1.1% max |
| Residual solvents | Meet the requirement |
| Assay | 98.0-102.0% |
| Conclusion | Comply with USP34 |
L-DOPA—Carbidopa and Parkinson’s Disease
- Levodopa and carbidopa are effective drugs for treating Parkinson’s disease.It is usually formulated with carbidopa in a ratio of 1:4 or 1:10 into regular tablets, sustained-release formulations, and other pharmaceutical preparations.
- Levodopa administration method：In addition to oral formulations, there are also methods such as enteral infusion (suitable for patients with advanced disease and severe motility fluctuations) and dry powder inhalation (levodopa pump).
- If you miss the scheduled dose of levodopa-carbidopa, the specific time to adjust the dosage can be determined based on the time remaining until the next dose.For example: If you have just missed your next dose and there is still a long time before the next dose, take the missed dose immediately, and keep the next dose at the same time;If it’s closer to the next dose, skip it.This is to avoid taking the medication too close together, which could lead to excessively high drug concentrations in the body and increase the risk of side effects.
- It is important to note that under no circumstances should the dosage of levodopa-carbidopa be doubled.Doubling the dosage can cause a sudden increase in drug concentration, which can lead to serious adverse reactions such as increased involuntary movements and mental confusion.
- Levodopa-carbidopa extended-release tablets should be swallowed whole or in half; they should not be chewed or crushed.This will disrupt the sustained-release properties of the drug, leading to a sudden release of the drug.
Get an Instant Quote Now
